Latest News and Press Releases

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Biopsy Devices - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.Global Biopsy Devices market size is estimated at...

CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

Hangzhou, China, May 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary,...

CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- — Trwały efekt terapeutyczny z istotnie niższym współczynnikiem niepowodzeń leczenia zmiany docelowej (TLF) – 2,7% wobec 7,2% (p=0,030) dla DynamX® w...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durata sostenuta dell’efficacia del trattamento con tassi di TLF significativamente inferiori (2,7% vs. 7,2%, p=0,030) con DynamX® rispetto al DES— —Tasso...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durabilidad sostenida del efecto del tratamiento y tasas de fracaso de la lesión objetivo significativamente menores (2,7 % frente a 7,2 %, p=0,030) con...

Paris, 21 mai 2025 (GLOBE NEWSWIRE) -- —Un effet thérapeutique durable avec des taux de TLF significativement inférieurs (2,7 % contre 7,2 %, p = 0,030) avec DynamX® par rapport au SEM— —Taux de...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES – –...

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower...